Clotting Disorders

Clotting Disorders

A collection of features and news articles published in ASH Clinical News related to clotting disorders.

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Updates on ASH Clinical Practice Guidelines in Development

In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists and...

Early Removal of Central Venous Catheters Does Not Increase Risk of PE

Among patients with a hematologic malignancy and central venous catheter–associated upper extremity deep vein thrombosis (UEDVT), removal of catheters within 48 hours did not...
How I Treat In Brief

How I Treat in Brief: Venous Thromboembolism in Sickle Cell Disease

Arun S. Shet, MD, from the NIH’s National Heart, Lung, and Blood Institute, and Ted Wun, MD, from UC Davis Comprehensive Cancer Center in...

FDA Expands Rivaroxaban’s Indication to Include Hospitalized Patients

The U.S. Food and Drug Administration (FDA) approved the direct oral anticoagulant rivaroxaban for the prevention of venous thromboembolism (VTE) in hospitalized, acutely ill...

Representing Hemostasis and Thrombosis: An Interview With Roy Silverstein, MD

2019 American Society of Hematology (ASH) President Roy Silverstein, MD, speaks about the goals of the ASH Working Group on Hemostasis and Thrombosis. What is...
You Make the Call

Reader Responses: How would you treat a patient with a prolonged PTT and antiphospholipid...

Here’s how readers responded to a You Make the Call question about a patient with a prolonged PTT and antiphospholipid antibodies. Disclaimer: ASH does not...
You Make the Call

How would you treat a patient with a prolonged PTT and antiphospholipid antibodies?

This month, Caroline Berube, MD, discusses treatment for a patient with a prolonged PTT and antiphospholipid antibodies. And don't forget to check out next month's...

Male Sex, Factor V Leiden Mutation Increase Recurrent VTE Risk After First Cerebral Venous...

A new study found that male sex and factor V Leiden mutation were associated with a higher risk of recurrent venous thromboembolism (VTE) after...

FDA Requires Boxed Warning for Tofacitinib

The U.S. Food and Drug Administration (FDA) has issued a Safety Announcement for the Janus kinase (JAK) inhibitor tofacitinib, after finding that patients taking...
Advertisement

Current Issue

February 2020, Volume 6, Issue 3

This issue examines the high price of treating hemophilia, asks whether CAR T-cell therapies are worth the cost, and more.